XML 56 R49.htm IDEA: XBRL DOCUMENT v3.24.3
Long-Term Obligations - Additional Information (Detail)
1 Months Ended 3 Months Ended 9 Months Ended
May 13, 2024
USD ($)
shares
May 31, 2024
USD ($)
shares
Sep. 30, 2019
USD ($)
Sep. 30, 2024
USD ($)
$ / shares
shares
Sep. 30, 2023
USD ($)
Sep. 30, 2024
USD ($)
Days
$ / shares
shares
Sep. 30, 2023
USD ($)
May 08, 2024
USD ($)
shares
Dec. 31, 2023
USD ($)
Aug. 01, 2023
$ / shares
shares
Oct. 31, 2018
USD ($)
Subsequent Event [Line Items]                      
Cash, cash equivalents and investments       $ 133,500,000   $ 133,500,000          
Debt instrument convertible threshold consecutive trading days | Days           5          
Description of debt instrument convertible period           during the five-business day period immediately after any five consecutive trading day period          
Principal amount of notes used in conversion rate           $ 1,000          
Debt instrument convertible threshold maximum percentage of product of last reported sale price of common stock           98.00%          
Percentage of redemption fee           3.00%          
Debt instrument exchange amount   $ 148,000,000                  
Exercise price | $ / shares       $ 0.0001   $ 0.0001          
Gain on extinguishment of debt       $ 0 $ 0 $ 44,702,000 $ 0        
Line of Credit [Member]                      
Subsequent Event [Line Items]                      
Quarterly cash payments           6.25%          
Secured Overnight Financing Rate [Member] | Line of Credit [Member]                      
Subsequent Event [Line Items]                      
Rate margin           9.25%          
Base Rate [Member] | Line of Credit [Member]                      
Subsequent Event [Line Items]                      
Rate margin           3.00%          
Maximum [Member]                      
Subsequent Event [Line Items]                      
Prepayment premium           5.00%          
Exercise price | $ / shares                   $ 2.25  
Minimum [Member]                      
Subsequent Event [Line Items]                      
Prepayment premium           3.00%          
Exercise price | $ / shares                   $ 1.1  
May 2024 Warrants [Member]                      
Subsequent Event [Line Items]                      
Warrants purchased | shares       45,776,212   45,776,212   45,776,213      
Exercise price | $ / shares       $ 1.1   $ 1.1          
Conversion price description           The May 2024 Warrants are exercisable through May 13, 2029. If the closing price of our common stock exceeds two times the then current exercise price of the warrants, which is currently equal to $2.20, for 20 trading days during any 30 consecutive trading day period, we can require the holder to exercise the May 2024 Warrants.          
May 2024 Warrants [Member] | Maximum [Member]                      
Subsequent Event [Line Items]                      
Warrants purchased | shares 45,800,000 45,800,000                  
Percentage common stock outstanding       19.99%   19.99%          
May 2024 Warrants [Member] | Minimum [Member]                      
Subsequent Event [Line Items]                      
Percentage common stock outstanding       4.99%   4.99%          
Pre Funded Warrants [Member]                      
Subsequent Event [Line Items]                      
Exercise price | $ / shares       $ 0.0001   $ 0.0001          
Number of warrants unissued | shares       0   0          
Deferred Royalty Obligation [Member] | Level 3 [Member]                      
Subsequent Event [Line Items]                      
Deferred royalty obligation at fair value       $ 73,500,000   $ 73,500,000     $ 129,700,000    
HealthCare Royalty Partners IV LP [Member]                      
Subsequent Event [Line Items]                      
Maximum remaining amount   $ 128,300,000                  
HealthCare Royalty Partners IV LP [Member] | Warrant [Member]                      
Subsequent Event [Line Items]                      
Warrants purchased | shares                   250,000,000  
Revenue Interest Financing Agreement [Member]                      
Subsequent Event [Line Items]                      
Debt issuance costs       1,700,000   1,700,000          
First investment amount     $ 135,000,000                
Bifurcation of embedded derivatives       $ 263,300,000   $ 263,300,000          
Aggregate Royalties     $ 263,300,000                
Revenue Interest Financing Agreement [Member] | HealthCare Royalty Partners IV LP [Member]                      
Subsequent Event [Line Items]                      
Repayment terms           term may be shortened or extended depending on actual worldwide net product sales and upfront payments, milestones, and royalties. The repayment period expires on the earlier of (i) the date in which HCRx has received cash payments totaling $263.3 million or (ii) the legal maturity date of October 1, 2031. If HCRx has not received total payments equal to $263.3 million by September 2031, we will be required to pay an amount equal to $135.0 million plus a specific annual rate of return less payments previously paid to HCRx. In the event of a change of control, an event of default, including, among others, our failure to pay any amounts due to HCRx, insolvency, our failure to pay indebtedness when due, the revocation of regulatory approval of XPOVIO in the U.S. or our breach of any covenant contained in the Amended Revenue Interest Agreement and our failure to cure the breach within the prescribed time frame, we are obligated to pay HCRx an amount equal to $263.3 million less payments previously paid to HCRx.          
Amended Revenue Interest Agreement [Member]                      
Subsequent Event [Line Items]                      
Aggregate principal amount   135,000,000                  
Revenue Interest Agreement and Amended Revenue Interest Agreement [Member]                      
Subsequent Event [Line Items]                      
Debt instrument interest rate       16.08%   16.08%          
Revenue Interest Agreement and Amended Revenue Interest Agreement [Member] | HealthCare Royalty Partners IV LP [Member]                      
Subsequent Event [Line Items]                      
Cumulative payments   49,500,000   $ 140,900,000   $ 140,900,000          
Convertible Note Offering [Member]                      
Subsequent Event [Line Items]                      
Notes converted in to common stock, amount | shares           63.0731          
Notes converted in to common stock, shares           $ 1,000          
Notes, conversion price per share | $ / shares       $ 15.85   $ 15.85          
Term Loan [Member]                      
Subsequent Event [Line Items]                      
Aggregate principal amount   15,000,000                  
Debt issuance costs       $ 6,800,000   $ 6,800,000          
Contractual interest expense       $ 3,700,000   $ 5,800,000          
Debt discount and issuance costs amortized to interest expense, amortization period           4 years          
Expected life           4 years          
Debt instrument interest rate       17.86%   17.86%          
Interest expense on debt       $ 4,300,000   $ 6,700,000          
Amortization of debt issuance cost       600,000   900,000          
6% Convertible Senior Notes Due 2029 [Member]                      
Subsequent Event [Line Items]                      
Aggregate principal amount   111,000,000                  
6% Convertible Senior Notes Due 2029 [Member] | HealthCare Royalty Partners IV LP [Member]                      
Subsequent Event [Line Items]                      
Aggregate principal amount   5,000,000                  
Credit Agreement and Term Loan [Member] | Line of Credit [Member]                      
Subsequent Event [Line Items]                      
Cash, cash equivalents and investments       25,000,000   25,000,000          
Line of credit facility               $ 100,000,000      
2029 Notes [Member]                      
Subsequent Event [Line Items]                      
Aggregate principal amount $ 5,000,000     116,000,000   116,000,000          
Debt issuance costs       4,758,000   4,758,000          
Contractual interest expense       1,700,000   $ 2,700,000          
Debt discount and issuance costs amortized to interest expense, amortization period           5 years          
Notes, interest rate           6.00%          
Proceeds from convertible debt           $ 111,000,000          
Notes conversion price, percentage           130.00%          
Notes instrument, trading days | Days           20          
Debt instrument convertible threshold consecutive trading days | Days           30          
Percentage of redeem notes at premium with proceeds           101.00%          
Estimated fair value of convertible notes       $ 87,200,000   $ 87,200,000          
Debt instrument interest rate       26.94%   26.94%          
Long-term debt gross       $ 148,132,000   $ 148,132,000          
Gain on extinguishment of debt           44,700,000          
Initial fair value       78,900,000   78,900,000   $ 78,900,000      
Initial fair value adjustment           32,100,000          
Bifurcation of embedded derivatives       28,900,000   28,900,000          
Interest expense on debt       3,500,000   5,500,000          
Amortization of debt issuance cost       $ 1,800,000   $ 2,800,000          
2029 Notes [Member] | Maximum [Member]                      
Subsequent Event [Line Items]                      
Percentage common stock outstanding       19.99%   19.99%          
2029 Notes [Member] | Minimum [Member]                      
Subsequent Event [Line Items]                      
Percentage common stock outstanding       4.99%   4.99%          
2029 Notes [Member] | HealthCare Royalty Partners IV LP [Member]                      
Subsequent Event [Line Items]                      
Aggregate principal amount 5,000,000                    
2029 Notes [Member] | Convertible Note Offering [Member]                      
Subsequent Event [Line Items]                      
Notes converted in to common stock, amount | shares           444.4444          
Notes converted in to common stock, shares           $ 1,000          
Proceeds from convertible debt           $ 111,000,000          
Notes, conversion price per share | $ / shares       $ 2.25   $ 2.25          
2025 Notes [Member]                      
Subsequent Event [Line Items]                      
Aggregate principal amount   $ 24,500,000   $ 24,500,000   $ 24,500,000     172,500,000   $ 172,500,000
Debt issuance costs       5,600,000   5,600,000          
Contractual interest expense       184,000 1,293,000 $ 2,170,000 3,881,000        
Debt discount and issuance costs amortized to interest expense, amortization period           7 years          
Notes, interest rate           3.00%          
Notes, maturity date           Oct. 15, 2025          
Principal amount of notes used in conversion rate       1,000   $ 1,000          
Debt instrument, convertible latest date           Jun. 15, 2025          
Notes conversion price, percentage           130.00%          
Notes instrument, trading days | Days           20          
Debt instrument convertible threshold consecutive trading days | Days           30          
Notes, repurchase price           100.00%          
Estimated fair value of convertible notes       $ 19,200,000   $ 19,200,000     $ 87,900,000    
Expected life           7 years          
Debt instrument interest rate       3.53%   3.53%          
Long-term debt gross       $ 25,604,000   $ 25,604,000          
Interest expense on debt       217,000 1,498,000 2,518,000 4,478,000        
Amortization of debt issuance cost       $ 33,000 $ 205,000 $ 348,000 $ 597,000        
2025 Notes [Member] | Convertible Note Offering [Member]                      
Subsequent Event [Line Items]                      
Notes converted in to common stock, shares $ 148,000,000